Literature DB >> 26178759

Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?

Preeti Subhedar1, Michelle Stempel1, Anne Eaton2, Monica Morrow1, Mary L Gemignani3.   

Abstract

INTRODUCTION: We sought to determine if adoption of the Z0011 criteria was associated with removal of more sentinel lymph nodes (SLNs).
METHODS: In a retrospective review of a prospective database of breast cancer patients treated at our institution from 2006 to 2013, we identified 5213 eligible patients who elected to undergo breast-conserving surgery; 2372 were treated pre-Z0011 and 2841 post-Z0011. Clinicopathologic factors were collected, and univariate and multivariate models were fit to identify variables associated with number of SLNs removed.
RESULTS: Median patient age, 60 years, did not differ between groups. Median tumor size was similar in both groups: 1.1 (0.05-5.0) cm in the pre-Z0011 group and 1.2 (0.1-5.2) cm in the post-Z0011 group. The mean number of SLNs excised in the pre-Z0011 patients was 2.8 compared with 2.9 in post-Z0011 patients (p = 0.01). Three or fewer lymph nodes were removed in 1771 (75 %) pre-Z0011 patients compared with 2006 (71 %) post-Z0011 patients (p = 0.01). Factors associated with the removal of more SLNs on multivariate analysis included adoption of ACOSOG Z0011 criteria (p = 0.03), young age (p ≤ 0.0001), and large tumor size (p = 0.0005). Axillary lymph node dissection (ALND) was performed in 379 (16 %) patients pre-Z0011 compared with 68 (2 %) node-positive post-Z0011 patients (p < 0.0001).
CONCLUSIONS: Since the adoption of Z0011 criteria, we found significantly fewer patients undergoing ALND for positive SLNs. We noted a significant, slight shift in the removal of ≥4 SLNs. The Z0011 criteria were not associated with a clinically significant increase in the number of SLNs removed.

Entities:  

Mesh:

Year:  2015        PMID: 26178759      PMCID: PMC4688213          DOI: 10.1245/s10434-015-4698-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Measuring the impact of the American College of Surgeons Oncology Group Z0011 trial on breast cancer surgery in a community health system.

Authors:  Gerald Paul Wright; Megan E Mater; Holly L Sobel; Gregory M Knoll; Leon D Oostendorp; Marianne K Melnik; Mathew H Chung
Journal:  Am J Surg       Date:  2014-08-20       Impact factor: 2.565

2.  Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.

Authors:  Umberto Veronesi; Giuseppe Viale; Giovanni Paganelli; Stefano Zurrida; Alberto Luini; Viviana Galimberti; Paolo Veronesi; Mattia Intra; Patrick Maisonneuve; Francesca Zucca; Giovanna Gatti; Giovanni Mazzarol; Concetta De Cicco; Dario Vezzoli
Journal:  Ann Surg       Date:  2010-04       Impact factor: 12.969

3.  How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?

Authors:  Min Yi; Funda Meric-Bernstam; Merrick I Ross; Jeri S Akins; Rosa F Hwang; Anthony Lucci; Henry M Kuerer; Gildy V Babiera; Michael Z Gilcrease; Kelly K Hunt
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

4.  Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden.

Authors:  Karyn B Stitzenberg; Anthony A Meyer; Stacey L Stern; William G Cance; Benjamin F Calvo; Nancy Klauber-DeMore; Hong Jin Kim; Leah Sansbury; David W Ollila
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

5.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer.

Authors:  A E Giuliano; D M Kirgan; J M Guenther; D L Morton
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

6.  Factors influencing the number of sentinel lymph nodes identified in patients with breast cancer.

Authors:  Anees B Chagpar; David J Carlson; Alison L Laidley; Souzan E El-Eid; Terre Q McGlothin; Robert D Noyes; Phillip B Ley; Todd M Tuttle; Kelly M McMasters
Journal:  Am J Surg       Date:  2007-12       Impact factor: 2.565

7.  Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node?

Authors:  Peter Schrenk; Wolfgang Rehberger; Andreas Shamiyeh; Wolfgang Wayand
Journal:  J Surg Oncol       Date:  2002-07       Impact factor: 3.454

8.  The sentinel node in breast cancer--a multicenter validation study.

Authors:  D Krag; D Weaver; T Ashikaga; F Moffat; V S Klimberg; C Shriver; S Feldman; R Kusminsky; M Gadd; J Kuhn; S Harlow; P Beitsch
Journal:  N Engl J Med       Date:  1998-10-01       Impact factor: 91.245

9.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.

Authors:  Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

Review 10.  Clinical aspects of sentinel node biopsy.

Authors:  H S Cody
Journal:  Breast Cancer Res       Date:  2001-01-23       Impact factor: 6.466

View more
  3 in total

1.  Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?

Authors:  Jennifer L Baker; Shirin Muhsen; Emily C Zabor; Michelle Stempel; Mary L Gemignani
Journal:  Ann Surg Oncol       Date:  2018-11-30       Impact factor: 5.344

2.  Comparative Study between Sentinel Lymph Node Biopsy and Axillary Dissection in Patients with One or Two Lymph Node Metastases.

Authors:  Jina Lee; Jung Eun Choi; Sei Joong Kim; Sae Byul Lee; Min-Ki Seong; Joon Jeong; Chan Seok Yoon; Bong Kyun Kim; Woo Young Sun
Journal:  J Breast Cancer       Date:  2018-09-20       Impact factor: 3.588

3.  Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era.

Authors:  Fabio Corsi; Luca Sorrentino; Sara Albasini; Daniela Bossi; Carlo Morasso; Laura Villani; Marta Truffi
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.